Core Viewpoint - The article highlights the swift action taken by the Xiamen Market Supervision Administration in response to reports of false advertising related to "imported" blood sugar control drinks, leading to the removal of certain products from the market and ongoing investigations into the involved companies [1][4][5]. Regulatory Response - The Xiamen Market Supervision Administration has initiated an investigation into the companies involved in the false advertising of blood sugar control products, specifically targeting the "Kongtangwei" and "Breorqy" brands [1][5]. - The regulatory body has mandated the removal of product links and is conducting further investigations to address the reported violations [1][5][6]. Market Impact - The article notes that the false claims made by these products, such as being "imported" and having extraordinary effects on blood sugar control, misled consumers and posed challenges to diabetes treatment [4][5]. - The cost of the "Kongtangwei" product is estimated to be less than 10 yuan, while it is sold for over 100 yuan, indicating significant markup based on misleading claims [4]. Ongoing Issues - Despite the removal of certain products, many others continue to be sold with unchanged promotional content, indicating a persistent issue with false advertising in the market [7][8]. - The article points out that various other products, including chromium supplements and herbal teas, also make unverified claims regarding their effectiveness in controlling blood sugar levels [5][8]. Recommendations for Improvement - Experts suggest that regulatory efforts need to be strengthened, particularly in enhancing the oversight of e-commerce platforms to prevent the sale of products with exaggerated claims [8][9]. - There is a call for improved collaboration among regulatory bodies across different regions to ensure comprehensive monitoring and enforcement against misleading advertising practices [8][9].

Core Viewpoint - The article highlights the misleading marketing practices of certain dietary supplements claiming to control blood sugar levels, emphasizing that these products are not a cure for diabetes and may not have the efficacy they advertise [1][2][3]. Group 1: Product Claims and Marketing Tactics - Products like "Kongtangwei" and "Breorqy Bitter Melon Peptide Drink" falsely claim to be "imported from the USA" while being produced domestically [1][4]. - These products assert that they can repair pancreatic cells, reverse diabetes, and allow patients to stop medication, which is considered false advertising by medical experts [2][3]. - Marketing strategies include comparing their products unfavorably to established diabetes medications, emphasizing the supposed lack of side effects and dependency [9][10]. Group 2: Regulatory and Legal Concerns - Dietary supplements in China are classified as ordinary food and cannot legally claim therapeutic effects, which these products do [3][11]. - The advertising practices of these products violate Chinese advertising laws that prohibit non-medical products from claiming to treat diseases [11][12]. Group 3: Consumer Experiences and Feedback - Consumers report that despite using these products, their blood sugar levels did not improve, leading to refund requests and complaints about false advertising [19][21]. - Some consumers expressed skepticism about the authenticity of positive reviews, suspecting they may be fabricated [21][22]. Group 4: Production and Cost Analysis - The production cost of these products is significantly lower than their retail price, with estimates suggesting a production cost of around 10 yuan per bottle, while they are sold for over 160 yuan [24][25]. - The products are marketed as having advanced formulations, but the actual ingredients and their efficacy are often misrepresented [22][23]. Group 5: Scientific Validity of Ingredients - Ingredients like Noni juice and Bitter Melon peptide are claimed to have blood sugar-lowering effects, but medical professionals indicate that there is insufficient evidence to support these claims [27][28][29]. - Experts emphasize that no single product can effectively treat all diabetes patients, highlighting the need for individualized treatment plans [29].